GO:0034144 negative regulation of toll-like receptor 4 signaling pathway: Immune Brake Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034144 describes any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 4 (TLR4) signaling, a central innate immune sensing pathway for bacterial lipopolysaccharide (LPS).
• Negative regulation of TLR4 signaling is essential to prevent excessive inflammation; failure of these brakes contributes to sepsis, chronic inflammatory disease, and tissue injury.
• Multiple molecular brakes exist, including Tollip, RP105, IL-10-induced microRNA-146b, SIRT5-mediated TBK1 desuccinylation, lactate-GPR81 signaling, and small-molecule inhibitors such as TAK-242.
• TLR4 signaling can also be attenuated by RNA interference or shRNA targeting TLR4, demonstrating that reducing receptor availability negatively regulates the pathway.
• Dysregulated negative regulation of TLR4 signaling is implicated in sepsis, liver and pancreatic injury, cancer-associated muscle atrophy, and epithelial-mesenchymal transition.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect which genes causally regulate TLR4 signaling and to validate therapeutic targets.
Description
Toll-like receptor 4 (TLR4) is the primary sensor for bacterial lipopolysaccharide (LPS) and a key initiator of innate immune responses. Upon LPS binding, TLR4 triggers intracellular signaling cascades that activate NF-kB and interferon regulatory factors, driving production of pro-inflammatory cytokines. While this response is essential for host defense, uncontrolled TLR4 signaling can cause tissue damage, septic shock, and chronic inflammation. Therefore, negative regulation of TLR4 signaling (GO:0034144) represents a critical homeostatic mechanism that restrains the pathway. Researchers study this process to understand how inflammation is resolved and to identify therapeutic targets for inflammatory diseases. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental models relevant to GO:0034144.
negative regulation of toll-like receptor 4 signaling pathway At A Glance
| GO ID | GO:0034144 |
|---|---|
| GO term | negative regulation of toll-like receptor 4 signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of TLR4 signaling pathway; negative regulation of toll-like receptor 4 signalling pathway |
| Major function | Restraining TLR4-mediated innate immune activation to prevent excessive inflammation and tissue damage |
| Key negative regulators | Tollip, RP105, IL-10/miR-146b, SIRT5, GPR81 (lactate), TAK-242 |
| Associated diseases | Sepsis, liver and pancreatic injury, cancer-associated muscle atrophy, inflammatory disorders |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, cytokine assays |
What Is GO:0034144?
GO:0034144, negative regulation of toll-like receptor 4 signaling pathway, is defined by QuickGO as any biological process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 4 signaling pathway. In practice, this includes molecular mechanisms that degrade or inhibit TLR4 pathway components, induce decoy receptors, or activate intracellular phosphatases and microRNAs that dampen downstream signaling.
Why Is negative regulation of toll-like receptor 4 signaling pathway Important in Cell Biology?
Negative regulation of TLR4 signaling is vital because it prevents the innate immune system from causing collateral damage during infection and sterile inflammation. Without these brakes, persistent TLR4 activation drives pathologies such as sepsis, chronic liver disease, and cancer cachexia. Understanding GO:0034144 therefore informs the development of anti-inflammatory therapeutics and helps explain how endogenous molecules like lactate or IL-10 resolve inflammation.
• Prevents septic shock by limiting LPS-induced cytokine storms.
• Protects against liver and pancreatic injury in TLR4-mediated inflammation.
• Regulates epithelial-mesenchymal transition in biliary epithelial cells.
• Modulates cancer-associated muscle atrophy via p38-C/EBPbeta signaling.
• Controls macrophage inflammatory responses through TBK1 desuccinylation.
• Provides targets for small-molecule inhibitors like TAK-242.
• Involves microRNA-based feedback (miR-146b) induced by IL-10.
• Involves decoy receptors such as RP105 that block TLR4-MD-2 complex.
• Involves intracellular adaptors like Tollip that suppress IRAK activation.
• Offers CRISPR-based strategies to validate causal genes in inflammatory disease models.
What Happens During negative regulation of toll-like receptor 4 signaling pathway?
Initiation of TLR4 signaling and the need for negative regulation
In simple terms: When bacteria release LPS, TLR4 turns on inflammation; negative regulation is the brake that stops it from going too far.
LPS binds TLR4-MD-2, triggering dimerization and recruitment of adaptors like MyD88 and TRIF, which activate NF-kB and IRFs. This leads to pro-inflammatory cytokine production. Negative regulation begins when sensors detect sustained activation, engaging multiple inhibitory mechanisms.
Intracellular adaptor inhibition by Tollip
In simple terms: Tollip is a protein that binds to the TLR4 signaling complex and blocks downstream signals.
Tollip (TOLLIP) negatively regulates TLR-mediated signaling by associating with IRAK-1 and preventing its phosphorylation and degradation, thereby suppressing NF-kB activation. Overexpression of Tollip reduces LPS-induced cytokine production, while its knockdown enhances signaling.
Decoy receptor RP105 and soluble inhibitors
In simple terms: RP105 acts like a fake receptor that ties up TLR4's partner, preventing real signaling.
RP105 (CD180) is a TLR homolog that associates with MD-1 and inhibits TLR4 signaling by competing for MD-2 binding. RP105-deficient mice show enhanced LPS responses, demonstrating its role as a negative regulator.
MicroRNA-mediated feedback: miR-146b
In simple terms: IL-10 triggers a microRNA that shuts down TLR4 pathway proteins after inflammation starts.
IL-10 induces microRNA-146b, which targets IRAK1 and TRAF6, reducing TLR4 signaling and cytokine production. This represents a delayed negative feedback loop that resolves inflammation.
Metabolic and post-translational brakes: lactate-GPR81 and SIRT5
In simple terms: Lactate and SIRT5 are chemical signals that chemically modify or inhibit TLR4 pathway proteins.
Lactate activates GPR81 to suppress TLR4-mediated innate immunity and reduce liver/pancreatic injury. SIRT5 desuccinylates TBK1, inhibiting its kinase activity and dampening macrophage inflammatory responses in sepsis.
Pharmacological inhibition with TAK-242
In simple terms: TAK-242 is a drug that directly blocks TLR4 signaling.
TAK-242 (resatorvid) binds TLR4 and inhibits its signaling, attenuating cancer-associated muscle atrophy via the p38-C/EBPbeta pathway. This demonstrates that small molecules can mimic endogenous negative regulation.
Key Genes Involved in GO:0034144 negative regulation of toll-like receptor 4 signaling pathway
The following genes and proteins are experimentally validated participants in negative regulation of TLR4 signaling (GO:0034144).
| Gene | Major Role | Research Relevance |
|---|---|---|
| TOLLIP | Binds IRAK-1 and suppresses TLR4 signaling | Overexpression reduces LPS responses; KO enhances inflammation |
| RP105 (CD180) | Decoy receptor competing with TLR4 for MD-2 | RP105 KO mice show enhanced LPS sensitivity |
| IL10 | Induces miR-146b to downregulate IRAK1/TRAF6 | IL-10 KO models show uncontrolled TLR4 inflammation |
| MIR146B | Targets IRAK1 and TRAF6 mRNA | Overexpression mimics IL-10 anti-inflammatory effects |
| SIRT5 | Desuccinylates TBK1 to inhibit its activity | SIRT5 KO increases TBK1 activity and inflammation |
| TBK1 | Kinase in TLR4 pathway; inhibited by SIRT5 | Point mutation of succinylation sites alters signaling |
| HCAR1 (GPR81) | Lactate receptor mediating suppression of TLR4 | GPR81 KO abolishes lactate anti-inflammatory effects |
| TLR4 | Primary receptor; target of negative regulation | TLR4 shRNA reduces EMT in biliary cells |
| MYD88 | Adaptor; downstream of TLR4 | Target of miR-146b feedback |
| IRAK1 | Kinase; inhibited by Tollip and miR-146b | Key node for negative regulation |
| TRAF6 | E3 ligase; target of miR-146b | Knockdown mimics negative regulation |
| NFKB1 | Transcription factor driving cytokines | Readout of TLR4 pathway activity |
| MAPK14 (p38) | Kinase in TLR4 pathway; linked to muscle atrophy | TAK-242 inhibits p38-C/EBPbeta |
| CEBPB | Transcription factor downstream of p38 | Mediates muscle atrophy in cancer |
| MD-2 (LY96) | Co-receptor for LPS; binds RP105 | Competition with RP105 inhibits signaling |
| CD14 | LPS co-receptor | Facilitates TLR4 activation |
| TICAM1 (TRIF) | Adaptor for MyD88-independent pathway | Target for negative regulation |
| TRAF3 | Adaptor in TRIF pathway | Modulated by negative regulators |
How Is negative regulation of toll-like receptor 4 signaling pathway Regulated?
Negative regulation of TLR4 signaling is itself tightly regulated at multiple levels. IL-10 induces miR-146b as a delayed feedback loop. Metabolic signals such as lactate via GPR81 suppress innate immunity. Post-translational modifications, including SIRT5-mediated desuccinylation of TBK1, provide rapid inhibition. Pharmacological agents like TAK-242 can exogenously enforce negative regulation.
negative regulation of toll-like receptor 4 signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRT5 | Sepsis | SIRT5 KO macrophages; LPS challenge |
| TOLLIP | Inflammatory disorders | Tollip overexpression/KO in macrophages |
| RP105 | LPS hypersensitivity | RP105 KO mice |
| HCAR1 (GPR81) | Liver/pancreatic injury | GPR81 KO mice with lactate treatment |
| TLR4 | Biliary fibrosis/EMT | TLR4 shRNA in biliary epithelial cells |
Sepsis and cytokine storm
In sepsis, excessive TLR4 activation leads to lethal cytokine release. Negative regulators such as SIRT5 and Tollip are critical to restrain TBK1 and IRAK1, respectively. Loss of these brakes exacerbates inflammation and organ failure.
Liver and pancreatic injury
Lactate-GPR81 signaling negatively regulates TLR4 and inflammasome-mediated inflammation, reducing liver and pancreatic injury in experimental models. This highlights the therapeutic potential of enhancing negative regulation.
Cancer-associated muscle atrophy
TAK-242 inhibits TLR4 signaling and attenuates cancer-associated muscle atrophy via the p38-C/EBPbeta pathway, linking negative regulation of TLR4 to muscle wasting in cancer.
Epithelial-mesenchymal transition in biliary epithelium
TLR4 shRNA attenuates LPS-induced epithelial-mesenchymal transition in intrahepatic biliary epithelial cells, suggesting that reducing TLR4 signaling (negative regulation) may limit fibrosis.
From negative regulation of toll-like receptor 4 signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SIRT5 desuccinylation of TBK1 negatively regulate TLR4 signaling? | SIRT5 KO and TBK1 point-mutant knock-in macrophages |
| Does Tollip inhibit IRAK1 to dampen TLR4 signaling? | Tollip overexpression and KO cell lines |
| Does RP105 act as a decoy receptor for TLR4? | RP105 KO mice and reconstitution |
| Does miR-146b mediate IL-10 negative feedback? | miR-146b overexpression and sponge knockdown |
| Does GPR81 mediate lactate suppression of TLR4? | GPR81 KO mice with lactate infusion |
| Can TAK-242 mimic negative regulation in muscle atrophy? | Cancer cachexia mouse model treated with TAK-242 |
How to Study the negative regulation of toll-like receptor 4 signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR KO | Loss of gene function | Validate negative regulators |
| RNA-seq | Transcriptome changes | Identify feedback loops |
| Proteomics | Protein modifications | Detect TBK1 desuccinylation |
| ELISA | Cytokine secretion | Quantify inflammation |
| Luciferase reporter | NF-kB activity | Screen inhibitors |
| Western blot | Protein phosphorylation | Assess IRAK1/TBK1 status |
| Flow cytometry | Surface TLR4/MD-2 | Measure receptor availability |
| shRNA knockdown | Gene silencing | Reduce TLR4 expression |
CRISPR knockout and knockdown
CRISPR-Cas9 knockout of candidate negative regulators (e.g., TOLLIP, RP105, SIRT5) followed by LPS stimulation and cytokine profiling can establish causality.
RNA sequencing and transcriptomics
RNA-seq after TLR4 activation in wild-type vs. knockout cells reveals global changes in inflammatory gene expression and identifies feedback loops like miR-146b.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can detect succinylation, phosphorylation, and ubiquitination changes on TLR4 pathway components, as shown for TBK1 desuccinylation by SIRT5.
Cytokine and reporter assays
ELISA for TNF-alpha, IL-6, and IL-1beta, along with NF-kB luciferase reporters, provide quantitative readouts of negative regulation.
How CRISPR Can Be Used to Study GO:0034144 negative regulation of toll-like receptor 4 signaling pathway
Knockout
CRISPR knockout of negative regulators such as TOLLIP, RP105, or SIRT5 in macrophages or epithelial cells can demonstrate their role in restraining TLR4 signaling.
Point Mutation
Introducing point mutations in TBK1 succinylation sites can test whether SIRT5-mediated desuccinylation is required for negative regulation.
Knock-in
Knock-in of tagged Tollip or RP105 allows tracking their interaction with TLR4 complex and localization during negative regulation.
Overexpression
Overexpression of miR-146b or Tollip can mimic negative regulation and suppress LPS-induced cytokine production.
How EDITGENE Supports negative regulation of toll-like receptor 4 signaling pathway Research
Researchers studying negative regulation of toll-like receptor 4 signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening TLR4 signaling or is merely a bystander. EDITGENE provides CRISPR-based cell model services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of toll-like receptor 4 signaling pathway research.
Frequently Asked Questions About negative regulation of toll-like receptor 4 signaling pathway
What is GO:0034144?
GO:0034144 is the Gene Ontology term for negative regulation of toll-like receptor 4 signaling pathway, describing any process that stops, prevents, or reduces TLR4 signaling.
What genes are involved in negative regulation of TLR4 signaling?
Key genes include TOLLIP, RP105 (CD180), IL10, MIR146B, SIRT5, HCAR1 (GPR81), and TLR4 itself.
How does Tollip negatively regulate TLR4?
Tollip binds IRAK-1 and prevents its phosphorylation, suppressing downstream NF-kB activation.
What is the role of RP105 in TLR4 signaling?
RP105 is a decoy receptor that competes with TLR4 for MD-2, inhibiting LPS responses.
How does IL-10 suppress TLR4 signaling?
IL-10 induces microRNA-146b, which targets IRAK1 and TRAF6 to dampen TLR4 signaling.
What is the role of SIRT5 in sepsis?
SIRT5 desuccinylates TBK1, inhibiting its activity and reducing macrophage inflammation in sepsis.
Can lactate suppress TLR4 signaling?
Yes, lactate activates GPR81 to suppress TLR4-mediated innate immunity and reduce tissue injury.
What is TAK-242?
TAK-242 is a small-molecule inhibitor of TLR4 that mimics negative regulation and attenuates muscle atrophy.
How is TLR4 signaling negatively regulated in cancer?
TAK-242 inhibits TLR4 and reduces cancer-associated muscle atrophy via p38-C/EBPbeta.
What experimental models study negative regulation of TLR4?
CRISPR KO, point mutation, knock-in, overexpression, RNA-seq, and proteomics are commonly used.
Conclusion
GO:0034144 encompasses diverse molecular mechanisms that restrain TLR4 signaling, from decoy receptors and adaptor inhibitors to microRNAs and metabolic regulators. These brakes are essential for preventing inflammatory pathology and represent promising therapeutic targets. CRISPR-based models will continue to accelerate the discovery of causal negative regulators and their translation into clinical strategies.
References
- 1. Lu YC et al.. 2008. LPS/TLR4 signal transduction pathway.. Cytokine 42(2):145-151 PMID: 18304834
- 2. Zhang X et al.. 2024. Desuccinylation of TBK1 by SIRT5 regulates inflammatory response of macrophages in sepsis.. Cell Rep 43(12):115060 PMID: 39673708
- 3. Hoque R et al.. 2014. Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity.. Gastroenterology 146(7):1763-74 PMID: 24657625
- 4. Curtale G et al.. 2013. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b.. Proc Natl Acad Sci U S A 110(28):11499-504 PMID: 23798430
- 5. Tang S et al.. 2018. Toll-like receptor 4 shRNA attenuates lipopolysaccharide-induced epithelial-mesenchymal transition of intrahepatic biliary epithelial cells in rats.. Biomed Pharmacother 107:1210-1217 PMID: 30257335
- 6. Zhang G et al.. 2002. Negative regulation of toll-like receptor-mediated signaling by Tollip.. J Biol Chem 277(9):7059-65 PMID: 11751856
- 7. Divanovic S et al.. 2005. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.. Nat Immunol 6(6):571-8 PMID: 15852007
- 8. You Y et al.. 2025. TAK-242 inhibits toll-like receptor-4 signaling and attenuates cancer-associated muscle atrophy via the p38-C/EBPβ pathway.. J Mol Histol 56(6):347 PMID: 41123701
